DarioHealth Corp. (NASDAQ:DRIO) Sees Large Drop in Short Interest

DarioHealth Corp. (NASDAQ:DRIO) saw a large decline in short interest in December. As of December 15th, there was short interest totaling 60,781 shares, a decline of 64.9% from the November 30th total of 173,193 shares. Approximately 1.0% of the shares of the stock are sold short. Based on an average daily volume of 23,716 shares, the short-interest ratio is currently 2.6 days. Based on an average daily volume of 23,716 shares, the short-interest ratio is currently 2.6 days. Approximately 1.0% of the shares of the stock are sold short.

Institutional Inflows and Outflows

An institutional investor recently raised its position in DarioHealth stock. XTX Topco Ltd boosted its position in shares of DarioHealth Corp. (NASDAQ:DRIO) by 229.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 62,511 shares of the company’s stock after acquiring an additional 43,513 shares during the period. XTX Topco Ltd owned 0.14% of DarioHealth worth $42,000 at the end of the most recent quarter. 33.39% of the stock is owned by institutional investors.

DarioHealth Price Performance

Shares of DRIO traded up $0.13 during trading hours on Friday, hitting $10.17. 2,566 shares of the company were exchanged, compared to its average volume of 34,355. The firm has a fifty day simple moving average of $12.76 and a 200-day simple moving average of $12.33. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.55 and a quick ratio of 4.02. The company has a market capitalization of $68.75 million, a PE ratio of -0.91 and a beta of 1.08. DarioHealth has a one year low of $5.93 and a one year high of $31.00.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on DRIO shares. Cowen reiterated a “hold” rating on shares of DarioHealth in a research note on Friday, November 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of DarioHealth in a research note on Monday. Stifel Nicolaus set a $16.00 price target on DarioHealth in a research report on Friday, November 14th. Finally, Wall Street Zen upgraded DarioHealth from a “sell” rating to a “hold” rating in a report on Sunday, December 21st. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $32.00.

DarioHealth Company Profile

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.